Por favor, use este identificador para citar o enlazar este ítem: http://dspace.azti.es/handle/24689/1755
Ficheros en este ítem:
No hay ficheros asociados a este ítem.
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorCano, Ainara
dc.contributor.authorVazquez-Chantada, Mercedes
dc.contributor.authorConde-Vancells, Javier and Gonzalez-Lahera, Aintzane
dc.contributor.authorMosen-Ansorena, David
dc.contributor.authorBlanco, Francisco J. J.
dc.contributor.authorClement, Karine
dc.contributor.authorAron-Wisnewsky, Judith
dc.contributor.authorTran, Albert
dc.contributor.authorGual, Philippe
dc.contributor.authorGarcia-Monzon, Carmelo
dc.contributor.authorCaballeria, Joan
dc.contributor.authorCastro, Azucena
dc.contributor.authorMartinez-Chantar, Maria Luz
dc.contributor.authorMato, Jose M.
dc.contributor.authorZhu, Huiping
dc.contributor.authorFinnell, Richard H. H.
dc.contributor.authorAransay, Ana M. M.
dc.date.accessioned2024-03-12T11:49:18Z-
dc.date.available2024-03-12T11:49:18Z-
dc.date.issued2023
dc.identifierWOS:000938975200001
dc.identifier.urihttp://dspace.azti.es/handle/24689/1755-
dc.description.abstractLow serum folate levels are inversely related to metabolic associated fatty liver disease (MAFLD). The role of the folate transporter gene (SLC19A1) was assessed to clarify its involvement in lipid accumulation during the onset of MAFLD in humans and in liver cells by genomic, transcriptomic, and metabolomic techniques. Genotypes of 3 SNPs in a case-control cohort were initially correlated to clinical and serum MAFLD markers. Subsequently, the expression of 84 key genes in response to the loss of SLC19A1 was evaluated with the aid of an RT2 profiler-array. After shRNA-silencing of SLC19A1 in THLE2 cells, folate and lipid levels were measured by ELISA and staining techniques, respectively. In addition, up to 482 amino acids and lipid metabolites were semi-quantified in SLC19A1-knockdown (KD) cells through ultra-high-performance liquid chromatography coupled with mass spectrometry. SNPs, rs1051266 and rs3788200, were significantly associated with the development of fatty liver for the single-marker allelic test. The minor alleles of these SNPs were associated with a 0.6/-1.67-fold decreased risk of developing MAFLD. When SLC19A1 was KD in THLE2 cells, intracellular folate content was four times lower than in wild-type cells. The lack of functional SLC19A1 provoked significant changes in the regulation of genes associated with lipid droplet accumulation within the cell and the onset of NAFLD. Metabolomic analyses showed a highly altered profile, where most of the species that accumulated in SLC19A1-KD-cells belong to the chemical groups of triacylglycerols, diacylglycerols, polyunsaturated fatty acids, and long chain, highly unsaturated cholesterol esters. In conclusion, the lack of SLC19A1 gene expression in hepatocytes affects the regulation of key genes for normal liver function, reduces intracellular folate levels, and impairs lipid metabolism, which entails lipid droplet accumulation in hepatocytes.
dc.language.isoEnglish
dc.publisherMDPI
dc.subjectNAFLD
dc.subjectMAFLD
dc.subjectfolate cycle
dc.subjectliver lipid metabolism
dc.subjectSNPs
dc.subjectgenomics
dc.subjecttranscriptomics
dc.subjectmetabolomics
dc.subjectFATTY LIVER-DISEASE
dc.subjectPLASMA HOMOCYSTEINE CONCENTRATIONS
dc.subjectNONALCOHOLIC STEATOHEPATITIS
dc.subjectGENETIC-VARIATION
dc.subjectACID
dc.subjectRISK
dc.subjectMETABOLISM
dc.subjectSTEATOSIS
dc.subjectPHOSPHATIDYLETHANOLAMINE
dc.subjectPHOSPHATIDYLCHOLINE
dc.titleImpaired Function of Solute Carrier Family 19 Leads to Low Folate Levels and Lipid Droplet Accumulation in Hepatocytes
dc.typeArticle
dc.identifier.journalBIOMEDICINES
dc.format.volume11
dc.contributor.funderCYTED 2005-2007 [FIT010000-2005-0013]
dc.contributor.funderLa Caixa Foundation 2007-2009 [425]
dc.contributor.funder``Programme Hospitalier de Reserche Clinique�� Assistance Publique-Hopitaux de Paris [AOR 02076]
dc.contributor.funderCommission of the European Communities (Collaborative Project ``Hepatic and adipose tissue and functions in the metabolic syndrome�� HEPADIP) [LSHM-CT-2005-018734]
dc.contributor.funderEuropean Union [Health-F2-2009-241762, 634413]
dc.contributor.funderGobierno Vasco-Departamento de Salud [2013111114]
dc.contributor.funderMINECO [SAF2014-54658-R, CTQ2017-83810-R, PID2020-113225GB-I00, SEV-2016-0644]
dc.contributor.funderInstituto de Salud Carlos III [PIE/00031]
dc.contributor.funderEITB Maratoia [BIO15/CA/014]
dc.contributor.funderBasque Foundation for Health Innovation and Research
dc.contributor.funderBBVA Foundation
dc.contributor.funderInstituto de Salud Carlos III, Spain [13/01299, 17/00535]
dc.contributor.funderEuropean FEDER funds
dc.contributor.funderFrench Government (National Research Agency, ANR) [ANR-15-CE14-0016-0]
dc.contributor.funderINSERM (France)
dc.contributor.funderAssociation Francaise pour l'Etude du Foie (AFEF)
dc.contributor.funderDepartment of Industry, Tourism and Trade of the Government of the Autonomous Community of the Basque Country
dc.contributor.funderInnovation Technology Department of the Bizkaia County
dc.contributor.funderAgence Nationale de la Recherche (ANR) [ANR-15-CE14-0016] Funding Source: Agence Nationale de la Recherche (ANR)
dc.identifier.e-issn2227-9059
dc.identifier.doi10.3390/biomedicines11020337
Aparece en las tipos de publicación: Artículos científicos



Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.